Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antibody drug conjugates
Biotech
Lilly buys ADC specialist CrossBridge Bio in vague $300M deal
Eli Lilly has agreed to a $300 million biobuck acquisition of CrossBridge Bio, aiming to advance its dual-payload ADC pipeline.
Will Maddox
Apr 14, 2026 8:00am
Akari locks arms with WuXi XDC to develop and manufacture ADC
Apr 8, 2026 11:30am
Roche returns to MediLink with $570M near-term payments for ADC
Jan 9, 2026 5:40am
Celltrion looks beyond biosims with $350M antibody deal option
Nov 19, 2025 9:35am
Genmab sheds another clinical ADC from $1.8B ProfoundBio buy
Nov 17, 2025 2:17pm
AstraZeneca drops MASH drug over disappointing data
Nov 6, 2025 5:21am
